137 related articles for article (PubMed ID: 12512385)
1. Clinical development of mammalian target of rapamycin inhibitors.
Dancey JE
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1101-14. PubMed ID: 12512385
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of target of rapamycin inhibitors.
Easton JB; Houghton PJ
Expert Opin Ther Targets; 2004 Dec; 8(6):551-64. PubMed ID: 15584862
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin's resurrection: a new way to target the cancer cell cycle.
Garber K
J Natl Cancer Inst; 2001 Oct; 93(20):1517-9. PubMed ID: 11604470
[No Abstract] [Full Text] [Related]
4. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
5. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
7. Current development of mTOR inhibitors as anticancer agents.
Faivre S; Kroemer G; Raymond E
Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
[TBL] [Abstract][Full Text] [Related]
8. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
10. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
11. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Ren H; Chen M; Yue P; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Cancer Lett; 2012 Dec; 325(2):139-46. PubMed ID: 22781393
[TBL] [Abstract][Full Text] [Related]
12. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes.
Pham PT; Heydrick SJ; Fox HL; Kimball SR; Jefferson LS; Lynch CJ
J Cell Biochem; 2000 Sep; 79(3):427-41. PubMed ID: 10972980
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin.
Meric-Bernstam F; Mills GB
Semin Oncol; 2004 Dec; 31(6 Suppl 16):10-7; discussion 33. PubMed ID: 15799239
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Ikezoe T; Nishioka C; Tasaka T; Yang Y; Komatsu N; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2006 Oct; 5(10):2522-30. PubMed ID: 17041096
[TBL] [Abstract][Full Text] [Related]
19. Regulation of translation initiation by FRAP/mTOR.
Gingras AC; Raught B; Sonenberg N
Genes Dev; 2001 Apr; 15(7):807-26. PubMed ID: 11297505
[No Abstract] [Full Text] [Related]
20. Therapeutic targets: MTOR and related pathways.
Dancey JE
Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]